Search

Your search keyword '"Rans, Kato"' showing total 16 results
Start Over Author "Rans, Kato"
16 results on '"Rans, Kato"'

2. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

Author

Rans, Kato, Charlien, Berghen, Filip, Ameye, Olivier, De Hertogh, Julie, den Hartog, Céderic, Draulans, Herlinde, Dumez, Benedikt, Engels, Karolien, Goffin, Annouschka, Laenen, Nick, Liefhooghe, Kenneth, Poels, Carl, Salembier, Koen, Slabbaert, Hans, Vandendriessche, Ben, Vanneste, Steven, Joniau, and Gert, De Meerleer

Published
2022
Full Text
View/download PDF

3. The impact of progression‐directed therapy on survival in metastatic castration‐refractory prostate cancer: MEDCARE phase 3 trial.

Author

Rans, Kato, Goffin, Karolien, Joniau, Steven, Daugaard, Gedske, Hartog, Julie, Van Wynsberge, Lodewijk, and De Meerleer, Gert

Abstract

Background Methods and Design Discussion Metastatic castration‐refractory prostate cancer (mCRPC) presents a therapeutic challenge despite advancements in treatment. Once mCRPC is attained, patients face limited survival prospects. Next‐line systemic treatment (NEST) is the standard of care for progressive mCRPC, encompassing various therapeutic options with associated toxicity and costs. In patients with oligoprogressive mCRPC, data suggest that progression‐directed therapy (PDT), such as metastasectomy or stereotactic body radiotherapy, delays the initiation of NEST.The MEDCARE phase III trial aims to assess the impact of PDT on overall survival (OS) in oligoprogressive mCRPC. In this multicentric, randomised, prospective trial, we aim to randomise 246 patients in 1:1 allocation ratio between the standard‐of‐care therapy (surveillance or NEST) or PDT while continuing the current systemic treatment. Patients will be stratified based on number of progressive lesions (one vs ≥one), location of progressive lesions (local recurrence, N or M1a vs M1b or M1c) and previous systemic therapy (palliative androgen‐deprivation therapy [pADT] vs pADT + androgen receptor‐targeted agent or patients who received docetaxel in the past). The primary endpoint is OS, and the secondary endpoints include quality of life, radiographic progression‐free survival (PFS), modified PFS, prostate cancer‐specific survival and PDT‐induced toxicity.This is the first randomised phase 3 trial in the setting of PDT in patients with oligoprogressive mCRPC with OS as the primary endpoint. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Elective nodal radiotherapy in prostate cancer

Author

De Meerleer, Gert, Berghen, Charlien, Briganti, Alberto, Vulsteke, Christof, Murray, Julia, Joniau, Steven, Leliveld, Anne M, Cozzarini, Cesare, Decaestecker, Karel, Rans, Kato, Fonteyne, Valerie, De Hertogh, Olivier, and Bossi, Alberto

Published
2021
Full Text
View/download PDF

10. sj-docx-2-tct-10.1177_15330338231154088 - Supplemental material for Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study

Author

Fonteyne, Valérie, Danckaert, Willeke, Ost, Piet, Berghen, Charlien, Vandecasteele, Katrien, Vanneste, Ben, Rans, Kato, Liefhooghe, Nick, Wallaert, Steven, and Paelinck, Leen

Subjects
110320 Radiology and Organ Imaging, FOS: Clinical medicine, Biochemistry, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tct-10.1177_15330338231154088 for Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study by Valérie Fonteyne, Willeke Danckaert, Piet Ost, Charlien Berghen, Katrien Vandecasteele, Ben Vanneste, Kato Rans, Nick Liefhooghe, Steven Wallaert and Leen Paelinck in Technology in Cancer Research & Treatment

Published
2023
Full Text
View/download PDF

12. In Regard to Zelefsky et al

Author

Rans, Kato, primary, De Meerleer, Gert, additional, Joniau, Steven, additional, Baten, Adinda, additional, Berkovic, Patrick, additional, Lambrecht, Maarten, additional, and Berghen, Charlien, additional

Published
2021
Full Text
View/download PDF

13. The role of radiation therapy and particle therapy in renal cell carcinoma: current evidence and future perspectives

Author

Berghen, Charlien, primary, Albersen, Maarten, additional, De Roover, Robin, additional, Rans, Kato, additional, Beuselinck, Benoit, additional, Decaestecker, Karel, additional, Poels, Kenneth, additional, Otte, Francois-Xavier, additional, Joniau, Steven, additional, Haustermans, Karin, additional, and De Meerleer, Gert, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results